Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A molecular model on a lab bench in a research laboratory

Jul 14, 2026

Chai Discovery Raises $400 Million Series C To Advance AI-Driven Molecular Design

Chai Discovery has successfully secured $400 million in Series C funding, propelling its AI-driven molecular design platform toward enhanced drug discovery capabilities.The financing round, which values the company at $3.8 billion, was spearheaded by Index Ventures and included significant participation from other notable investors such as Kleiner Perkins, Sequoia Capital, and Bain Capital Ventures. Existing backers, including OpenAI and Thrive Capital, also contributed to this substantial inves
Flat illustration of a cancer cell and in silico model

Jul 14, 2026

Biotech companies tout benefits of AI-assisted drug development

Biotechnology firms are increasingly integrating artificial intelligence (AI) into drug development processes, showcasing its potential to revolutionize research methodologies and outcomes. At the Kadans Oncology Summit in Paris, discussions highlighted various applications of AI, particularly in drug target discovery and the development of preclinical cancer models.One notable innovation is the use of in silico models, which aim to replace traditional cellular and animal testing methods. Paul D
A minimalist representation of biotechnology tools and health tech collaboration.

Jul 14, 2026

AusBiotech and Oktopi announce partnership to boost Australian life sciences

AusBiotech has formed a strategic partnership with Oktopi to enhance support for its members in the Australian life sciences sector.The collaboration aims to provide AusBiotech members with access to Oktopi's AI-driven platform at discounted rates, further enriching the organization's Business Solutions Program. This initiative will connect professionals in biotechnology, medical technology, and health tech with customized tools and pricing to facilitate medicine development.Rebekah Cassidy, CEO
A flat illustration of a pill and a brain silhouette on a solid background.

Jul 13, 2026

Insilico Medicine and CMS Enter $177 Million AI-Powered Drug Discovery Collaboration

Insilico Medicine and China Medical System Holdings Limited (CMS) have entered a significant $177 million collaboration focused on AI-driven drug discovery for central nervous system disorders. This partnership builds on their initial collaboration just three months prior, highlighting a strong and productive relationship.The agreement facilitates a joint effort in advancing a drug discovery program that combines Insilico's generative AI capabilities, particularly its PandaOmics platform, with C
Minimalist illustration of T cell engager and antibody-drug conjugate

Jul 13, 2026

AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline

Ardigen and VERAXA Biotech have announced a collaboration aimed at enhancing drug discovery through AI technologies, specifically targeting cancer therapies.This partnership will leverage Ardigen's expertise in AI and computational biology to support VERAXA's BiTAC pipeline, which focuses on T cell engagers (TCEs) and antibody-drug conjugates (ADCs). By utilizing AI-enabled tools, the collaboration aims to optimize the selection of cancer target pairs, thereby improving therapeutic designs while
Minimalist illustration of tumor-associated antigens

Jul 13, 2026

Veraxa Uses AI to Advance BiTAC Pipeline

Veraxa Biotech AG has partnered with Ardigen S.A. to leverage AI in enhancing its BiTAC pipeline, which focuses on bispecific T cell engagers and antibody-drug conjugates. This collaboration aims to develop computational tools for selecting synergistic cancer target combinations that fit Veraxa’s innovative therapeutic architecture.The BiTAC platform features a unique mechanism where a T cell engager or ADC is divided into two inactive precursor molecules. These reconstitute a functional agent o
A colorful molecule model on a lab bench surrounded by equipment.

Jul 13, 2026

Insilico Medicine and CMS deepen AI drug discovery tie-up with new CNS collaboration

Insilico Medicine has expanded its collaboration with China Medical System Holdings (CMS) to enhance AI-driven drug discovery for central nervous system (CNS) conditions. This partnership builds on a previous agreement established three months prior.The new collaboration focuses on a unique mechanism of action discovered through Insilico's PandaOmics platform, which is integral to its Pharma.ai suite that includes tools for molecule generation and trial outcome predictions. Under this deal, Insi
Minimalist illustration of T cell engager and antibody-drug conjugate

Jul 13, 2026

AI partnership aims to sharpen cancer target selection at VERAXA

VERAXA Biotech has announced a collaboration with Ardigen to enhance its cancer therapy pipeline through AI-driven drug discovery.This partnership aims to optimize the selection of cancer target pairs for VERAXA’s BiTAC® platform, which focuses on conditionally active T cell engagers (TCEs) and antibody-drug conjugates (ADCs). By leveraging Ardigen's AI capabilities, VERAXA intends to improve the identification of synergistic target combinations, potentially increasing the success rates of its d
A vial of a drug compound on a lab bench in a dimly lit laboratory.

Jul 13, 2026

VERAXA Biotech AG Announces AI Collaboration with Ardigen to Support BiTAC Cancer Therapeutics Pipeline

VERAXA Biotech AG has entered a collaboration with Ardigen to enhance its BiTAC cancer therapeutics pipeline through AI-driven strategies.On July 13, 2026, VERAXA Biotech AG announced its partnership with Ardigen S.A., an AI-focused company known for its contributions to precision medicine. This collaboration aims to advance VERAXA's BiTAC® pipeline, which includes T cell engagers (TCEs) and antibody drug conjugates (ADCs). A central aspect of this partnership is the integration of AI to improve
A drug compound vial on a lab table with a research notebook

Jul 13, 2026

Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases

Insilico Medicine and China Medical System (CMS) have expanded their collaboration to enhance AI-driven drug discovery in central nervous system (CNS) diseases. This partnership builds on their previous agreement, focusing on a mass-market indication with a novel mechanism of action identified through Insilico's PandaOmics platform.The collaboration aims to leverage Insilico's advanced AI capabilities in drug discovery alongside CMS's robust R&D expertise and commercialization strategies. Insili
Flat illustration of RNA and DNA structures

Jul 13, 2026

Syngenis banks $4M pre-float to power AI-driven biotech platform

Syngenis Labs has successfully raised $4 million in a pre-float funding round aimed at advancing its AI-driven biotech platform, which focuses on RNA and DNA-based medicines. This funding will enable the Perth-based company to enhance its capabilities and position itself within the burgeoning genetic medicine sector in Australia.The funding round, which saw strong interest from investors, is intended to support the development of Syngenis' integrated ecosystem for RNA and DNA therapeutics. The c
A minimalist illustration of a pill and a molecule on a solid background.

Jul 11, 2026

Takeda Pharmaceutical (TSE:4502) Taps Pharma.AI For Drug Discovery, Is The Stock Still Cheap?

Takeda Pharmaceutical has recently partnered with Insilico Medicine’s Pharma.AI platform, enhancing its drug discovery capabilities through artificial intelligence. This collaboration comes as the company experiences a notable rise in its stock price, reflecting investor optimism about its future prospects.Year-to-date, Takeda's shares have increased by 8.5%, and the company has achieved a total shareholder return of 26.82% over the past year. However, there has been a slight decline of 6.94% in